An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Trial Status: Enrolling by Invitation
This is a multi-center, open-label, study to evaluate the safety and efficacy of ublituximab (TG-1101) in combination with TGR-1202 for patients who have progressed on treatment arms previously enrolled in Protocol UTX-TGR-304
Inclusion Criteria
- Prior treatment in clinical trial UTX-TGR-304
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Exclusion Criteria
- Patients refractory to ublituximab + TGR-1202
- Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
California
Duarte
City of Hope Comprehensive Cancer Center
Status: ACTIVE
Contact: Tanya Siddiqi
Phone: 800-826-4673
Email:
becomingapatient@coh.org
Connecticut
New Haven
Kansas
Kansas City
University of Kansas Cancer Center
Status: ACTIVE
Overland Park
University of Kansas Cancer Center-Overland Park
Status: ACTIVE
Westwood
University of Kansas Hospital-Westwood Cancer Center
Status: ACTIVE
Missouri
Kansas City
The University of Kansas Cancer Center-South
Status: ACTIVE
University of Kansas Cancer Center - North
Status: ACTIVE
New Hampshire
Lebanon
Dartmouth Hitchcock Medical Center
Status: ACTIVE
Contact: Frederick Lansigan
Phone: 800-639-6918
North Carolina
Durham
Duke University Medical Center
Status: ACTIVE
Contact: Danielle M Brander
Phone: 888-275-3853
Email:
danielle.brander@dm.duke.edu
Oregon
Portland
OHSU Knight Cancer Institute
Status: CLOSED_TO_ACCRUAL
Pennsylvania
Philadelphia
University of Pennsylvania / Abramson Cancer Center
Status: ACTIVE
Virginia
Charlottesville
University of Virginia Cancer Center
Status: ACTIVE
Washington
Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: ACTIVE
Trial Phase Phase II
Trial Type Treatment
Lead Organization
TG Therapeutics Inc
- Primary ID UTX-TGR-204
- Secondary IDs NCI-2016-01255
- Clinicaltrials.gov ID NCT02656303